Hosted on MSN2d
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/YNevro Corp. NVRO reported a loss per share of 41 cents in the third quarter of 2024, narrower than the year-ago quarter’s ...
Nevro Corp (NVRO) has disclosed a new risk, in the Accounting & Financial Operations category. Nevro Corp faces a significant financial risk due to potential declines in its market capitalization, ...
Nevro (NYSE:NVRO – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, ...
Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.
Zacks.com on MSN3d
Nevro (NVRO) Reports Q3 Loss, Tops Revenue EstimatesNevro (NVRO) delivered earnings and revenue surprises of 37.80% and 4.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Baird reaffirms Nevro with a Neutral and raises the price target from $5 to $6. RBC Capital reiterates Nevro with a Sector ...
Check the time stamp on this data. Updated AI-Generated Signals for Nevro Corp. (NVRO) available here: NVRO.
The Redwood City, California-based company said it had a loss of 41 cents per share. Losses, adjusted for non-recurring gains, came to 51 cents per share. The results exceeded Wall Street expectations ...
Detailed price information for Akoya Biosciences Inc (AKYA-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback